News & Events about Adc Therapeutics Sa.
ADC Therapeutics (NYSE:ADCT Get Rating) had its price objective cut by analysts at Morgan Stanley from $7.00 to $5.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has an equal weight rating on the stock. Morgan Stanleys price target points...
PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics PR Newswire LONDON, Jan. 5, 2023 London-based deal experts are the advisors for this collaboration and...
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11th at 3:00 p.m. PT. A live webcast of the presentation will be available...
ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi) today announced the European Commission (EC) has granted conditional marketing authorization for the use of ZYNLONTA (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL...
ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose Pepe Carmona as Chief Financial Officer (CFO), effective December 19, 2022. He will serve on the Companys executive leadership team and succeeds Jenn Creel, who is leaving to pursue other opportunities. This press release...